MedTrace Logo

Safety, Tolerability and Efficacy of MBS2320 in Patients With Rheumatoid Arthritis

NCT03139136 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 121

Last updated 2019-08-14

No results posted yet for this study

Summary

Rheumatoid arthritis (RA) affects 1 percent of the population worldwide and up to 40 percent of patients don't respond to current treatments. MBS2320, the drug being tested in this trial, represents a new approach to treating RA, with the potential not only to reduce levels of inflammation but to also directly prevent bone damage.The aim of this project is to test the safety, tolerability and efficacy of MBS2320 in patients with RA in combination with an existing treatment, methotrexate.

Conditions

Interventions

DRUG

MBS2320

As described in the arm descriptions

DRUG

Placebo

As described in the arm descriptions

Sponsors & Collaborators

  • Modern Biosciences Ltd

    lead INDUSTRY

Principal Investigators

  • Inga Bodrug, MD · Arensia Exploratory Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-05-30
Primary Completion
2018-11-16
Completion
2019-08-13

Countries

  • Georgia
  • Moldova
  • Romania

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03139136 on ClinicalTrials.gov